Related Experiment Video

Updated: Sep 24, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

668

Functions of non-coding RNAs in regulating cancer drug targets

Binshu Chai, Zhongliang Ma, Xianyi Wang

    Acta Biochimica Et Biophysica Sinica
    |May 10, 2022
    PubMed

    Insights

    Precision medicine improves cancer treatment efficiency. This review summarizes targeted therapies like epidermal growth factor receptor (EGFR) targeting and immunotherapy, highlighting the role of non-coding RNAs (ncRNAs) in overcoming drug resistance.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genetics

    Background:

    • Precision medicine has significantly advanced cancer treatment efficacy.
    • Targeted therapies, particularly epidermal growth factor receptor (EGFR) inhibitors, and immunotherapies are key components of precision oncology.
    • Despite advancements, drug resistance remains a significant challenge in cancer therapy.

    Purpose of the Study:

    • To review current targeted cancer treatments, including EGFR inhibitors and immunotherapies.
    • To explore the emerging role of non-coding RNAs (ncRNAs) in cancer development and treatment response.
    • To summarize how ncRNAs influence the efficacy of anticancer drugs and potentially overcome resistance.

    Main Methods:

    • Literature review of recent studies on targeted cancer therapy.
    • Analysis of research on the function of non-coding RNAs in various cancers.
    • Synthesis of information regarding ncRNA involvement in drug resistance mechanisms.

    Main Results:

    • EGFR-targeted therapies offer improved selectivity and reduced side effects compared to traditional chemotherapy.
    • Immunotherapy, especially immune checkpoint inhibitors, has emerged as a major cancer treatment modality.
    • Non-coding RNAs (ncRNAs) are increasingly recognized for their critical roles in tumorigenesis and modulating treatment outcomes.

    Conclusions:

    • Targeted therapies and immunotherapies represent significant progress in precision cancer treatment.
    • Non-coding RNAs (ncRNAs) present a promising area for understanding and potentially overcoming drug resistance.
    • Further research into ncRNAs could lead to novel strategies for enhancing the effectiveness of current cancer therapies.
    Keywords:
    EGFRdrug resistanceimmune checkpoint inhibitornon-coding RNA (ncRNA)precision medicine

    More Related Videos

    CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

    CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

    Published on: April 25, 2022

    2.5K
    An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

    An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

    Published on: May 21, 2019

    8.5K

    Related Concept Videos

    lncRNA - Long Non-coding RNAs02:39

    lncRNA - Long Non-coding RNAs

    In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
    9.0K
    Types of RNA01:23

    Types of RNA

    Overview
    Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
    RNA...
    68.0K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.9K
    MicroRNAs01:22

    MicroRNAs

    MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
    3.1K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.9K
    Experimental RNAi02:15

    Experimental RNAi

    RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
    6.3K